- Reduce cost of nearly every generic drug by >70%
- Prices are less than typical insurance
17/ Thinking about Valuation
At the current estimated IPO price and shares, GDRX will trade roughly:
- 25x 2019 Revenues
- 62x 2019 EBITDA
- 119x 2019 Pre-tax Profits
They're also growing 57% compounded since 2016.
18/ Concluding Thoughts
Alright, deep breath! We made it through another S-1.
Click below to read the unrolled thread version on the @MacroOps website. While you're there, don't be afraid to subscribe to our free newsletter: macro-ops.com/goodrx-gdrx-s-…
• • •
Missing some Tweet in this thread? You can try to
force a refresh